Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04709848
Other study ID # 20HH6406
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 2021
Est. completion date December 2021

Study information

Verified date January 2021
Source Imperial College Healthcare NHS Trust
Contact Paul Arkell, MBChB
Phone 02033113311
Email paul.arkell@nhs.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Strongyloidiasis is a worm infection which affects more than 100 million people, mostly in Africa, Asia and Latin America, and can cause severe illness in people with reduced immunity. In the UK, the number of people with Strongyloides is not known. At Imperial College Healthcare NHS Trust (ICHNT) , screening for Stongyloides has recently been introduced as a standard-of-care for all patients undergoing BMT. In this study, investigators will perform two cross-sectional surveys and report the prevalence of Strongyloides in BMT recipients at ICHNT , as well as comparing clinical outcomes before/after the introduction of routine testing.


Description:

Strongyloidiasis is a worm infection which affects more than 100 million people, mostly in Africa, Asia and Latin America. Infection can persist for decades, and usually causes mild symptoms. In some people with reduced immune systems (for example those who have bone marrow transplantation), the worms can multiply and cause severe illness and death. In the UK, the number of people with Strongyloides is not known. However, in many other non-tropical countries, rates are high in immigrant populations (including those who are having bone marrow transplantation, BMT). At ICHNT, screening for Stongyloides has recently been introduced as a standard-of-care for all patients undergoing BMT. All adult patients with forthcoming BMT at ICHNT will now be screened. Additionally, any patients who have already undergone BMT in the last two years will be screened as part of a look-back exercise as part of their clinical care. In this study, investigators will perform two cross-sectional surveys. Those who underwent BMT between Jun 2018 - July 2020 will form a 'pre-screening group', and those between July 2020 - July 2021 will form a 'screened group'. It is anticipated that 320 participants will be included in the pre-screening group and 160 in the screened-group (total 480). Data will be collected retrospectively and the prevalence of Strongyloides in BMT recipients at ICHNT will be reported. Comparison of clinical outcomes between the first and second groups will be undertaken, in order to determine whether the introduction of screening has had an impact.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 480
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients - Under care of Haematology at ICHNT - Undergoing BMT Jun 2018 - July 2020 ('pre-screening group') or July 2020 - July 2021 ('screened group') Exclusion Criteria: - Age < 18 years (i.e. managed as paediatric BMT) - Previous BMT but no Strongyloides serology result available at the time of data collection

Study Design


Related Conditions & MeSH terms


Intervention

Other:
None - standard of care
Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Imperial College Healthcare NHS Trust

Outcome

Type Measure Description Time frame Safety issue
Primary Strongyloides seropositivity Baseline
Secondary BMT outcome Bloodstream infection Within first 12 months after BMT
Secondary BMT outcome Respiratory disease Within first 12 months after BMT
Secondary BMT outcome Clinically significant diarrhoea Within first 12 months after BMT
Secondary BMT outcome CNS infection Within first 12 months after BMT
Secondary BMT outcome Graft vs. host disease Within first 12 months after BMT
Secondary BMT outcome Length-of-hospital-stay Within first 12 months after BMT
Secondary BMT outcome Antibiotic usage (defined daily doses) Within first 12 months after BMT
Secondary BMT outcome ICU admission Within first 12 months after BMT
Secondary BMT outcome Strongyloides hyperinfection syndrome Within first 12 months after BMT
Secondary BMT outcome Mortality Within first 12 months after BMT
See also
  Status Clinical Trial Phase
Completed NCT04999774 - Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study
Recruiting NCT05868005 - Delivering a Multi-disease Screening Tool to Migrant Populations N/A
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Terminated NCT03605758 - Treatment of Strongyloides Infection Phase 3
Recruiting NCT06373835 - Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis Phase 2
Completed NCT01570504 - Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis Phase 3
Completed NCT02105714 - Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders N/A
Completed NCT00207753 - Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections N/A
Completed NCT00001245 - Study of Patients With Strongyloides Stercoralis Infection N/A